2212 GMT - Pathology services provider Healius is in the recovery room, but Barrenjoey is skeptical that the company can reach performance targets laid out at its investor day yesterday. Healius wants to grow revenue at 6% and make a high-single-digit Ebit margin by FY 2027. Analyst Saul Hadassin says this implies Ebit growing at a compound annual rate of 120% from FY 2025-FY 2027. "While we anticipate an improvement in operating performance, this target looks difficult to deliver, particularly in light of looming cuts to VitB12/mid-stream urine tests," Barrenjoey says. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 27, 2025 18:12 ET (22:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。